Evidence map›Paper›PMID 42357446›Full record

ArticleMolecules (Basel, Switzerland)2026

Method for Isolating Hypericin from

Dmitry Medvedev, Vasilisa Dalinina, Polina Golik, Polina Lavrinova, Ekaterina Plotnikova, Maksim Usachev, Veronika Usatova, Mikhail Grin, Tatiana Abakumova, Petr Ostroverkhov

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dmitry MedvedevDepartment of Chemistry and Technology of Biologically Active Compounds, Medicinal and Organic Chemistry, Institute of Fine Chemical Technologies, MIREA-Russian Technological University, 86 Vernadsky Avenue, 119571 Moscow, Russia.ORCID 0009-0008-3618-4629
Vasilisa DalininaLaboratory of Synthetic Neurotechnologies, Pirogov Russian National Medical University, 117997 Moscow, Russia.
Polina GolikDepartment of Chemistry and Technology of Biologically Active Compounds, Medicinal and Organic Chemistry, Institute of Fine Chemical Technologies, MIREA-Russian Technological University, 86 Vernadsky Avenue, 119571 Moscow, Russia.
Polina LavrinovaDepartment of Chemistry and Technology of Biologically Active Compounds, Medicinal and Organic Chemistry, Institute of Fine Chemical Technologies, MIREA-Russian Technological University, 86 Vernadsky Avenue, 119571 Moscow, Russia.
Ekaterina PlotnikovaDepartment of Chemistry and Technology of Biologically Active Compounds, Medicinal and Organic Chemistry, Institute of Fine Chemical Technologies, MIREA-Russian Technological University, 86 Vernadsky Avenue, 119571 Moscow, Russia.ORCID 0000-0001-8711-6919
Maksim UsachevDepartment of Chemistry and Technology of Biologically Active Compounds, Medicinal and Organic Chemistry, Institute of Fine Chemical Technologies, MIREA-Russian Technological University, 86 Vernadsky Avenue, 119571 Moscow, Russia.ORCID 0000-0002-8266-6337
Veronika UsatovaFederal Center of Brain Research and Neurotechnologies, Federal Medical Biological Agency, 117997 Moscow, Russia.ORCID 0009-0004-0984-3773
Mikhail GrinDepartment of Chemistry and Technology of Biologically Active Compounds, Medicinal and Organic Chemistry, Institute of Fine Chemical Technologies, MIREA-Russian Technological University, 86 Vernadsky Avenue, 119571 Moscow, Russia.
Tatiana AbakumovaLaboratory of Synthetic Neurotechnologies, Pirogov Russian National Medical University, 117997 Moscow, Russia.
Petr OstroverkhovDepartment of Chemistry and Technology of Biologically Active Compounds, Medicinal and Organic Chemistry, Institute of Fine Chemical Technologies, MIREA-Russian Technological University, 86 Vernadsky Avenue, 119571 Moscow, Russia.

Funding

Russian Science Foundation 22-75-10151-PRussian Science Foundation 22-75-10151-P.
6 · The paper itself

Abstract

Hypericin (Hyp) is a naturally occurring photosensitizer (PS) exhibiting a broad spectrum of biological activities. However, its high hydrophobicity significantly limits its medical applicability. This study aimed to develop an efficient method for extracting Hyp from

Indexed as

HypericumMicellesPerylenePhotosensitizing AgentsAnimalsAnthracenesCell Line, TumorCell SurvivalMicePlant ExtractsPoloxamerAnthraceneshypericinMicellesPerylenePhotosensitizing AgentsPlant ExtractsPoloxamerglioblastomahypericinmicellesphotodynamic therapyphotosensitizerPluronic F-127

Identifiers

PMID42357446
PMCPMC13305305

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.